Anti-Aging

SS-31

Also known as: Elamipretide, Bendavia, MTP-131

Clinical Trials
Share:

Key Facts: SS-31

Category
Anti-Aging
FDA Status
Not FDA Approved
Clinical Status
Phase 3 Clinical Trials
Administration
Subcutaneous injection or IV infusion
Typical Dose
10-40 mg daily
Frequency
Once or twice daily
Evidence Level
Human Trials
Duration
Variable by condition
Also Known As
Elamipretide, Bendavia, MTP-131

What to Expect

A mitochondria-targeted peptide that improves cellular energy production. Being developed for heart failure and mitochondrial diseases.

Mechanism of Action

SS-31 concentrates 1000-fold in mitochondria, binding to cardiolipin on the inner membrane. It optimizes electron transport chain function, reduces reactive oxygen species, and prevents cardiolipin peroxidation during cellular stress.

Research Summary

Phase 2/3 trials for Barth syndrome and heart failure. Studies show improved cardiac function, exercise capacity, and mitochondrial efficiency. Demonstrates benefits in ischemia-reperfusion injury models.

Clinical Status:Phase 3 Clinical Trials
Trial Progress:Phase III
Pre
I
II
III
IV
FDA

Dosing Information

Human Trials·Human studies conducted, not FDA approved

Typical Dosing

Community experience

Common Dose

10-40 mg daily

Range

10-80 mg daily

Frequency

Once or twice daily

Mitochondrial peptide (Elamipretide). In clinical trials for mitochondrial diseases. Limited availability.

Research Dosing

Scientific studies

Doses from clinical trials

Doses from Studies

Duration

Variable by condition

Administration

Subcutaneous injection or IV infusion

Timing & Administration

Best Time to Take

Morning

Once daily

Food Recommendation

With or without food

Why This Timing?

SS-31 (Elamipretide) targets mitochondria. Morning use supports daytime energy production.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • Injection site reactions (very common - 80%)
  • Headache
  • Dizziness
  • Nausea
  • May trigger histamine release - use caution with MCAS or histamine sensitivity
  • No serious adverse events in trials
  • FDA approved September 2025

References

Related Peptides

Peptides commonly compared with SS-31 or used in similar applications.

Want updates on SS-31 research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Educational Information Only

This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.